“Efficacy and Safety of Bimekizumab in Patients With Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study With Randomized Withdrawal”. 2020. SKIN The Journal of Cutaneous Medicine 4 (6): s83. https://doi.org/10.25251/skin.4.supp.83.